Category Oncology
-
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Cancer Immunotherapy Paves the Way for Better Understanding of COVID-19
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0820Published: August 2020Expires: 7/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: COVID-19 , Cancer Immunotherapies -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Cancer Immunotherapy Paves the Way for Better Understanding of COVID-19 ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0820Published: August 2020Expires: 7/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: COVID-19 , Cancer Immunotherapies -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Androgen Deprivation Therapy Could Protect Men Against COVID-19
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0720Published: July 2020Expires: 7/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Androgen Deprivation Therapy , COVID-19 -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Androgen Deprivation Therapy Could Protect Men Against COVID-19 ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0720Published: July 2020Expires: 7/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Androgen Deprivation Therapy , COVID-19 -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Genomic Sequencing Initiative Advances Angiosarcoma Research
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0620Published: June 2020Expires: 6/1/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Angiosarcoma , Genomics -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Genomic Sequencing Initiative Advances Angiosarcoma Research ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0620Published: June 2020Expires: 6/1/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Angiosarcoma , Genomics -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Rising Role of the Microbiome in Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0520Published: May 2020Expires: 4/30/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Microbiome -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} The Rising Role of the Microbiome in Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0520Published: May 2020Expires: 4/30/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Cancer , Microbiome -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Slows Progression in Refractory HER2+ Breast Cancer
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OT0420Published: April 2020Expires: 3/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Breast Cancer -
{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Drug Slows Progression in Refractory HER2+ Breast Cancer ((Non-Physician Credit))
{{ evaluation.question.text }}{{choice.text}}{{evaluation.answerSet[0].text}}Test Code: OTN0420Published: April 2020Expires: 3/31/2022Sources: Oncology TimesDetailsRequired Passing Score: 7/10 (70%)Categories: Hematology , OncologySpecialties: Hematology, OncologyTopics: Breast Cancer